Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

INBX holding history

Inhibrx Biosciences, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

INBX overviewAll 13F holders of INBXFull Q2 2026 holdings

Shares (Q2 2026)
1,308,051
Value
$123.9M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of INBX by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,308,051$123.9M<0.1%+44,973+3.6%AddedHolders
Q1 20261,263,078$84.9M<0.1%+95,350+8.2%AddedHolders
Q4 20251,167,728$92.3M<0.1%+724,872+163.7%AddedHolders
Q3 2025442,856$14.9M<0.1%+415,048+1,492.5%AddedHolders
Q2 202527,808$396.8K<0.1%−9,092−24.6%ReducedHolders
Q1 202536,900$516.2K<0.1%−2,815−7.1%ReducedHolders
Q4 202439,715$611.6K<0.1%−199,525−83.4%ReducedHolders
Q3 2024239,240$3.75M<0.1%+3,324+1.4%AddedHolders
Q2 2024235,916$3.34M<0.1%−313,553−57.1%ReducedHolders
Q1 2024549,469$19.2M<0.1%+252,550+85.1%AddedHolders
Q4 2023296,919$11.3M<0.1%−85,851−22.4%ReducedHolders
Q3 2023382,770$7.02M<0.1%−1,885−0.5%ReducedHolders
Q2 2023384,655$9.99M<0.1%+8,435+2.2%AddedHolders
Q1 2023376,220$7.10M<0.1%+119,202+46.4%AddedHolders
Q4 2022257,018$6.33M<0.1%+95,985+59.6%AddedHolders
Q3 2022161,033$2.89M<0.1%+20,682+14.7%AddedHolders
Q2 2022140,351$1.59M<0.1%−144,068−50.7%ReducedHolders
Q1 2022284,419$6.34M<0.1%+228,052+404.6%AddedHolders
Q4 202156,367$2.46M<0.1%+53,099+1,624.8%AddedHolders
Q3 20213,268$108.0K<0.1%−23,066−87.6%ReducedHolders
Q2 202126,334$724.0K<0.1%−8,894−25.2%ReducedHolders
Q1 202135,228$707.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.